These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28552675)

  • 1. The era of 3Rs implementation in developmental and reproductive toxicity (DART) testing: Current overview and future perspectives.
    Beekhuijzen M
    Reprod Toxicol; 2017 Sep; 72():86-96. PubMed ID: 28552675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The way forward in reproductive/developmental toxicity testing.
    Spielmann H
    Altern Lab Anim; 2009 Dec; 37(6):641-56. PubMed ID: 20105000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing strategies for embryo-fetal toxicity of human pharmaceuticals. Animal models vs. in vitro approaches: a workshop report.
    van der Laan JW; Chapin RE; Haenen B; Jacobs AC; Piersma A
    Regul Toxicol Pharmacol; 2012 Jun; 63(1):115-23. PubMed ID: 22449444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated decision-tree testing strategies for developmental and reproductive toxicity with respect to the requirements of the EU REACH legislation.
    Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Feb; 36(1):65-80. PubMed ID: 18333715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated decision-tree testing strategies for developmental and reproductive toxicity with respect to the requirements of the EU REACH legislation.
    Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Oct; 36 Suppl 1():123-38. PubMed ID: 19025336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICH guidelines--implementation of the 3Rs (refinement, reduction, and replacement): incorporating best scientific practices into the regulatory process.
    Ohno Y
    ILAR J; 2002; 43 Suppl():S95-8. PubMed ID: 12388859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study of the zebrafish assay as an alternative method to screen for developmental toxicity and embryotoxicity using a training set of 27 compounds.
    Selderslaghs IW; Blust R; Witters HE
    Reprod Toxicol; 2012 Apr; 33(2):142-54. PubMed ID: 21871558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Struggles for equivalence: in vitro developmental toxicity model evolution in pharmaceuticals in 2006.
    Chapin R; Stedman D; Paquette J; Streck R; Kumpf S; Deng S
    Toxicol In Vitro; 2007 Dec; 21(8):1545-51. PubMed ID: 17137747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement, reduction, and replacement of animal use for regulatory testing: future improvements and implementation within the regulatory framework.
    Richmond J
    ILAR J; 2002; 43 Suppl():S63-8. PubMed ID: 12388854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of a novel integrated toxicity testing strategy incorporating "3R" principles of animal research to evaluate the safety of a new agrochemical sulfoxaflor.
    Terry C; Rasoulpour RJ; Saghir S; Marty S; Gollapudi BB; Billington R
    Crit Rev Toxicol; 2014 May; 44 Suppl 2():1-14. PubMed ID: 24832550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for the optimisation of in vivo experiments in accordance with the 3Rs philosophy.
    Madden JC; Hewitt M; Przybylak K; Vandebriel RJ; Piersma AH; Cronin MT
    Regul Toxicol Pharmacol; 2012 Jun; 63(1):140-54. PubMed ID: 22446816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A strategy for safety assessment of chemicals with data gaps for developmental and/or reproductive toxicity.
    Blackburn K; Daston G; Fisher J; Lester C; Naciff JM; Rufer ES; Stuard SB; Woeller K
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):202-15. PubMed ID: 25910676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Third FRAME Toxicity Committee: working toward greater implementation of alternatives in toxicity testing.
    Combes RD; Balls M; Bansil L; Barratt M; Bell D; Botham P; Broadhead C; Clothier R; George E; Fentem J; Jackson M; Indans I; Loizou G; Navaratnam V; Pentreath V; Phillips B; Stemplewski H; Stewart J
    Altern Lab Anim; 2004 Jun; 32 Suppl 1B():635-42. PubMed ID: 23581152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Working in partnership to advance the 3Rs in toxicity testing.
    Holmes AM; Creton S; Chapman K
    Toxicology; 2010 Jan; 267(1-3):14-9. PubMed ID: 19903508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New animal-free concepts and test methods for developmental toxicity and peripheral neurotoxicity.
    Leist M
    Altern Lab Anim; 2017 Nov; 45(5):253-260. PubMed ID: 29112453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity.
    Hewitt M; Ellison CM; Enoch SJ; Madden JC; Cronin MT
    Reprod Toxicol; 2010 Aug; 30(1):147-60. PubMed ID: 20006701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.